* Says authorization of SOF/VEL is supported by data from
four phase 3 studies, Astral-1, Astral-2, Astral-3 and Astral-4
The post BRIEF-Gilead Sciences says European Commission grants marketing authorization for Epclusa appeared first on NASDAQ.
BRIEF-Gilead Sciences says European Commission grants marketing authorization for Epclusa
